A5056975051- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Protein Tyrosine Phosphatases
- Gastric Cancer Management and Outcomes
- Neutropenia and Cancer Infections
- Cancer, Hypoxia, and Metabolism
- Pancreatic and Hepatic Oncology Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Peptidase Inhibition and Analysis
- PI3K/AKT/mTOR signaling in cancer
- Cancer Research and Treatments
- Cancer Mechanisms and Therapy
- Cancer therapeutics and mechanisms
- Synthesis and biological activity
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Helicobacter pylori-related gastroenterology studies
- Cancer Cells and Metastasis
- Cytokine Signaling Pathways and Interactions
Okayama University Hospital
2016-2025
Okayama University
2013-2024
Japanese Red Cross Society, Japan
2021
Tokyo Medical and Dental University
2020
Weatherford College
2020
Kawasaki Medical School
2013-2017
National Defense Medical College
2013-2016
Okayama Shoka University
2010-2015
Chugoku Central Hospital
2011-2014
AbbVie (United States)
2014
P001 - Sepsis impairs the capillary response within hypoxic capillaries and decreases erythrocyte oxygen-dependent ATP efflux R. M. Bateman, D. Sharpe, J. E. Jagger, C. G. Ellis P002 Lower serum immunoglobulin G2 level does not predispose to severe flu. Solé-Violán, López-Rodríguez, Herrera-Ramos, Ruíz-Hernández, L. Borderías, Horcajada, N. González-Quevedo, O. Rajas, Briones, F. Rodríguez de Castro, Gallego P003 Brain protective effects of intravenous through inhibition complement...
Trastuzumab deruxtecan (T-DXd) 5.4 and 6.4 mg/kg showed robust antitumor activity in multiple cancer indications; however, T-DXd has not been evaluated patients with previously treated human epidermal growth factor receptor 2-mutant (
Histochemical examination for argentaffin cells in 382 gastric and 81 intestinal carcinomas was carried out, revealed that 3.1% of 2.5% contained as an integral element the tumor. Occurrence these specific predominantly encountered among diffuse carcinoma stomach. A hitherto undescribed case stomach containing numerous is reported, term "diffuse argentaffinoma" suggested. The findings obtained may provide background possible presence cancer patients who have a carcinoid syndrome.
IntroductionWe aimed to evaluate the efficacy and safety of nanoparticle albumin-bound (nab-) paclitaxel for previously treated patients with advanced NSCLC.MethodsIn this randomized, open-label, noninferiority phase 3 trial, we enrolled NSCLC cytotoxic chemotherapy. Patients were randomly allocated (1:1) receive docetaxel (60 mg/m2) on day 1 or nab-paclitaxel (100 days 1, 8, 15 a 21-day cycle. The primary end point was overall survival (OS) analyzed an intention-to-treat...
BackgroundBRAF V600 mutations are common in melanoma, thyroid, and non-small-cell lung cancers. Despite dabrafenib trametinib being standard treatments for certain cancers, their efficacy across various solid tumours remains unelucidated. The BELIEVE trial assessed the of with BRAF V600E/R or non-V600 mutations.MethodsBetween October 1, 2019, June 2022, at least 50 patients measurable seven without diseases examined were enrolled a subcohort (NCCH1901, jRCTs031190104). mutated tumour cases...
This paper reports on the development and validation of a real-time reverse transcription-loop-mediated isothermal amplification assay (RT-LAMP) targeting genomic large RNA segment Rift Valley fever virus (RVFV). The set six designed RT-LAMP primers identified strains RVFV isolated in geographically distinct areas over period 50 years; there was no cross-reactivity with other genetically related unrelated arboviruses. When testing serial sera plasma from sheep experimentally infected...
Abstract Introduction Immune checkpoint inhibitors (ICIs) have demonstrated long survival for the treatment of advanced non-small cell lung cancer (NSCLC). However, effect and safety ICI rechallenge not been fully evaluated. The aim this study was to investigate efficacy in NSCLC patients. Methods We defined ‘rechallenge’ as re-administration ICIs patients who were previously treated with discontinued any reason, received subsequent chemotherapy. retrospectively analyzed histories 434 from...
Electron microscopy of two cases clear cell sarcoma tendons and aponeuroses showed different fine structures. On the basis these differences a proposed division is made melanotic synovial types tumor. A subsequent comparative histological study carried out on tumors that there were criteria to separate sarcoma. Using eleven further in files Tumor Registry subdivided. Review material eight type one was are which not clearly classifiable into either group. The present observations indicate...
A case of clear-cell sarcoma patellar tendon in a 31-year-old Japanese woman is reported, with an emphasis on its electron microscopic description. The chief fine structural findings were: 1. presence 2 types cells—large clear cell and small dark cell, abundant glycogen contents, 2. basement membrane pseudoacinal structures, 3. filopodia, 4. electron-dense bodies the cytoplasm. Some histogenetic relation to synovial tissue was suggested. It seems that tumor might fall under category sarcoma.
Abstract An irreversible ErbB family blocker is expected to inhibit tumors with activating epidermal growth factor receptor (EGFR) mutations more strongly than reversible EGFR tyrosine kinase inhibitors and overcome acquired resistance the T790M secondary mutation. Eleven-week-old transgenic mice Egfr exon 19 deletion mutation were treated afatinib, gefitinib, or vehicle for 4 weeks. All sacrificed at 15 weeks of age, number superficial left lung a long axis exceeding 1 mm was counted. The...
Tumors are presumed to contain a small population of cancer stem cells (CSCs) that initiate tumor growth and promote spreading. Multidrug resistance in CSCs is thought allow the evade conventional therapy. This study focused on expression CD133 CD87 because putative marker some cancers including lung, associated with stem-cell-like property small-cell lung (SCLC). Six SCLC cell lines were used. The levels analyzed by real-time quantitative reverse transcription-polymerase chain reaction flow...
Atezolizumab, an anti-programmed death-ligand 1 (PD-L1) agent, is effective and well tolerated in patients with pretreated advanced non-small-cell lung cancer (NSCLC). We assessed its efficacy safety Japanese through subgroup analyses of the phase 3 OAK study (NCT02008227).Key eligibility criteria this randomized, controlled, open-label, international include locally advanced/metastatic NSCLC, ≥ prior platinum-based chemotherapy, age 18 years, measurable disease (Response Evaluation Criteria...
Abstract Molecular agents targeting the epidermal growth factor receptor ( EGFR )‐, anaplastic lymphoma kinase ALK )‐ or c‐ ros oncogene 1 ROS1 ) alterations have revolutionized treatment of oncogene‐driven non‐small‐cell lung cancer (NSCLC). However, emergence acquired resistance remains a significant challenge, limiting wider clinical success these molecular targeted therapies. In this study, we investigated efficacy various agents, including erlotinib, alectinib, and crizotinib, combined...
Abstract Background We previously showed the 2-year OS rate, primary endpoint, of 90% in a phase II trial gefitinib induction followed by chemoradiotherapy (CRT) unresectable, stage III, EGFR-mutant, non-small-cell lung cancer (NSCLC). However, neither long-term survival data nor late-phase adverse event profiles have been presented. Patients and methods with III NSCLC were administered monotherapy for 8 weeks. After confirming no disease progression during therapy, cisplatin docetaxel on...
A comparative study was made of 800 Japanese and 627 American cases gastric carcinoma which had been surgically resected. The intention to show if there a difference in histologic appearance associated with geographic distribution incidence. In both Japan the United States adenocarcinoma predominant tumor type among patients over 50 years age. under 50. years, diffuse carcinoma. proportion studied age group from populations showed no significant statistical proportionate number each type....
As a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), osimeritnib is the standard treatment for patients with non-small cell lung cancer harboring EGFR T790M mutation; however, acquired resistance inevitably develops. Therefore, next-generation strategy warranted in osimertinib era. We investigated mechanism of to novel EGFR-TKI, naquotinib, goal developing strategy. established multiple naquotinib-resistant lines or osimertinib-resistant cells, two...
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, such as gefitinib and erlotinib, are effective for non-small cell lung cancer with activating EGFR mutations. However, even in patients an initial dramatic response to a drug, acquired resistance develops after 6-12 months. A secondary mutation of T790M amplification the MET gene account this resistance; however, mechanism(s) approximately 30% cases remain unknown. We established erlotinib-resistant line named PC-9/ER3 that...